Adam Crystal Biography and Net Worth

President, Research & Development of Tango Therapeutics

Adam Crystal oversees clinical and development operations as the Head of Research and Development at Tango Therapeutics. Most recently, Adam served as Chief Medical Officer of C4 Therapeutics where he oversaw the advancement of several oncology drug candidates into clinical trials and the preclinical development of further treatments for oncology. Prior to that, he was at Novartis Institutes for Biomedical Research, most recently as Senior Director, where he led several early clinical development programs. Adam has also served as a medical oncologist at Massachusetts General Hospital where he researched resistance mechanisms to targeted therapies.

After completing his Bachelor of Art in neuroscience at the University of Pennsylvania, Adam earned his MD and PhD in neuroscience from the University of Pennsylvania School of Medicine. He completed his internal medicine training at Massachusetts General Hospital and his fellowship in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute.

What is Adam Crystal's net worth?: The estimated net worth of Adam Crystal is at least $2.74 million as of May 1st, 2026. Dr. Crystal owns 115,743 shares of Tango Therapeutics stock worth more than $2,736,743 as of May 6th. This net worth approximation does not reflect any other investments that Dr. Crystal may own. Learn More about Adam Crystal's net worth.
How do I contact Adam Crystal?: The corporate mailing address for Dr. Crystal and other Tango Therapeutics executives is 12860 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. Tango Therapeutics can also be reached via phone at 857-320-4900 and via email at [email protected]. Learn More on Adam Crystal's contact information.
Has Adam Crystal been buying or selling shares of Tango Therapeutics?: In the last ninety days, Adam Crystal has sold $2,107,110.00 in Tango Therapeutics stock. Most recently, Adam Crystal sold 27,000 shares of the business's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $21.23, for a transaction totalling $573,210.00. Following the completion of the sale, the insider now directly owns 115,743 shares of the company's stock, valued at $2,457,223.89. Learn More on Adam Crystal's trading history.
Who are Tango Therapeutics' active insiders?: Tango Therapeutics' insider roster includes Douglas Barry (Chief Legal Officer), Daniella Beckman (CFO), Adam Crystal (President, Research & Development), Mace Rothenberg (Director), and Barbara Weber (CEO). Learn More on Tango Therapeutics' active insiders.
Are insiders buying or selling shares of Tango Therapeutics?: During the last year, insiders at the sold shares 16 times. They sold a total of 3,710,845 shares worth more than $30,423,371.68. The most recent insider tranaction occured on May, 1st when insider Adam Crystal sold 27,000 shares worth more than $573,210.00. Insiders at Tango Therapeutics own 6.5% of the company. Learn More about insider trades at Tango Therapeutics.
Information on this page was last updated on 5/1/2026.

Adam Crystal Insider Trading History at Tango Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/1/2026	Sell	27,000	$21.23	$573,210.00	115,743
4/15/2026	Sell	38,460	$25.00	$961,500.00	112,622
4/1/2026	Sell	27,000	$21.20	$572,400.00	112,622
3/25/2026	Sell	12,000	$20.11	$241,320.00	112,622
3/5/2026	Sell	20,251	$15.00	$303,765.00	112,622
2/25/2026	Sell	54,345	$12.77	$693,985.65	132,873
2/3/2026	Sell	18,452	$12.26	$226,221.52	187,218
2/4/2025	Sell	7,432	$2.99	$22,221.68	165,061
2/6/2024	Sell	4,288	$12.56	$53,857.28	123,561
11/1/2023	Sell	7,507	$8.39	$62,983.73	81,250

Adam Crystal Buying and Selling Activity at Tango Therapeutics

Tango Therapeutics Company Overview

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $23.62

$23.00

$24.30

50 Day Range

MA: $19.74

$11.14

$27.77

2 Week Range

Now: $23.62

$1.03

$28.41

Volume

1,475,247 shs

Average Volume

3,264,848 shs

Market Capitalization

$3.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22